RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000011.xml
Dtsch Med Wochenschr 2011; 136(22): 1165-1168
DOI: 10.1055/s-0031-1280531
DOI: 10.1055/s-0031-1280531
Endokrinologie und Diabetologie | Commentary
Endokrinologie, Onkologie© Georg Thieme Verlag KG Stuttgart · New York
Neue Therapieoptionen bei fortgeschrittenen Schilddrüsenkarzinomen
New therapeutic options for advanced thyroid cancerWeitere Informationen
Publikationsverlauf
Publikationsdatum:
24. Mai 2011 (online)

Schlüsselwörter
Schilddrüsenkarzinom - Multityrosinkinase-Inhibitoren - Sorafenib - Sunitinib - Vandetanib
Keywords
thyroid cancer - multi-tyrosine kinase inhibitors - sorafenib - sunitinib - vandetanib
Literatur
- 1
Bible K C, Suman V J, Molina J R. et al .
Efficacy of pazopanib
in progressive, radioiodine-refractory, metastatic differentiated
thyroid cancers.
Lancet Oncol.
2010;
11
962-972
MissingFormLabel
- 2
Carr L L, Mankoff D A, Goulart B H. et al .
Phase II study of daily
sunitinib in FDG-PET-positive, iodine-refractory differentiated
thyroid cancer and metastatic medullary carcinoma of the thyroid
with functional imaging correlation.
Clin Cancer Res.
2010;
16
5260-5268
MissingFormLabel
- 3
Cohen E EW, Needles B M, Cullen K J. et al .
Phase 2 study of sunitinib
in refractory thyroid cancer.
J Clin Oncol.
2008;
26 (Suppl.)
Abstract 6025
MissingFormLabel
- 4
Cohen E EW, Rosen L S, Vokes E E. et al .
Axitinib is an active traetment
for all histologic subtypes of advanced thyroid cancer.
J
Clin Oncol.
2008;
26
4708-4713
MissingFormLabel
- 5
De Souza J A, Busaidy N, Zimrin A. et al .
Phase II trial of sunitinib in medullary
thyroid cancer (MTC).
J Clin Oncol.
2010;
28 (Suppl.)
Abstract 5504
MissingFormLabel
- 6
Gupta-Abramson V, Troxel A B, Nellore A. et al .
Phase II trial of sorafenib in advanced
thyroid cancer.
J Clin Oncol.
2008;
26
4714-4719
MissingFormLabel
- 7
Hoftijzer H, Heemastra K A, Morreau H. et al .
Beneficial effects of sorafenib on tumor
progression, but not on radioiodine uptake, in patients with differentiated
thyroid carcinoma.
Eur J Endocrinol.
2009;
161
923-931
MissingFormLabel
- 8
Kloos R T, Ringel M D, Knopp M V. et al .
Phase II trial of sorafenib
in metastatic thyroid cancer.
J Clin Oncol.
2009;
27
1675-1684
MissingFormLabel
- 9
Kurzrock R, Cohen E E, Sherman S I. et al .
Long-term results in a cohort
of medullary thyroid cancer (MTC) patients (pts) in a phase I study
of XL 184 (BMS 907351), an oral inhibitor of MET, VEGFR2,
and RET.
J Clin Oncol.
2010;
28
(Suppl.)
Abstract 5502
MissingFormLabel
- 10
Lam E T, Ringel M D, Kloos R T. et al .
Phase II clinical trial
of sorafenib in metastatic medullary thyroid cancer.
J
Clin Oncol.
2010;
28
2323-2330
MissingFormLabel
- 11
Ravaud A, de la Fouchardiere C, Courbon F. et al .
Sunitinib in patients with refractory advanced
thyroid cancer.
J Clin Oncol.
2008;
26 Suppl
Abstract 6058
MissingFormLabel
- 12
Robinson B G, Paz-Ares L, Krebs A, Vasselli J, Haddad R.
Vandetanib (100 mg) in patients with locally advanced or metastatic
hereditary medullary thyroid cancer.
J Clin Endocrinol
Metab.
2010;
95
2664-2671
MissingFormLabel
- 13
Schlumberger M, Elisei R, Bastholt L. et al .
Phase II study of safety and efficacy of
motesanib in patients with progressive or symptomatic, advanced
or metastatic medullary thyroid cancer.
J Clin Oncol.
2009;
27
3794-3801
MissingFormLabel
- 14
Sherman S I, Wirth L J, Droz J -P. et al .
Motesanib diphosphate in
progressive differentiated thyroid cancer.
New Engl J
Med.
2008;
359
31-42
MissingFormLabel
- 15
Wells S A, Gosnell J E, Gagel R F. et al .
Vandetanib for the treatment
of patients with locally advanced or metastatic hereditary medullary
thyroid cancer.
J Clin Oncol.
2010;
28
767-772
MissingFormLabel
- 16
Wells S A, Robinson B G, Gagel R F. et al .
Vandetanib (VAN) in locally
advanced or metastatic medullary thyroid cancer (MTC).
J
Clin Oncol.
2010;
28 (Suppl.)
Abstract 5503
MissingFormLabel
- 17
Woyach J A, Shah M H.
New therapeutic
advances in the management of progressive thyroid cancer.
Endocrine
Rel Cancer.
2009;
16
715-731
MissingFormLabel
Prof. Dr. Christine Spitzweg
Medizinische Klinik und Poliklinik II
Klinikum
der Universität München – Campus Großhadern
Marchioninistr. 15
81377 München
Telefon: 089/7095-0
Fax: 089/7095-8887
eMail: Christine.Spitzweg@med.uni-muenchen.de